Healthcare >> Analyst Interviews >> March 26, 2013

Alternative Dosage Forms Create Barriers Against Competition in Generics

David Amsellem is a Managing Director and Senior Research Analyst at Piper Jaffray & Co., covering specialty pharmaceuticals. Prior to joining Piper Jaffray & Co. in 2008, Mr. Amsellem spent five years at Friedman Billings Ramsey, where he was a Senior Research Analyst covering small and midcap pharmaceuticals from 2006 to 2008, and a Senior Associate on the biotechnology equity research team from 2003 to 2006. Mr. Amsellem was recognized as the number one-ranked Analyst in North America for accuracy of earnings estimates in the pharmaceuticals sector in the 2008 Financial Times/StarMine Best Brokerage Analyst survey. Mr. Amsellem has more than 10 years of Wall Street experience, including work in life sciences investment and merchant banking at Prudential Vector Healthcare. Mr. Amsellem earned his B.S. from Cornell University. Profile
TWST: Please begin with a brief overview of your coverage, including some specific names you follow.

Mr. Amsellem: We have pretty broad and pretty deep coverage of the entire

Pin It on Pinterest

Share This